Protalix BioTherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1996
Net Income	8.31	-14.93	-27.58	-6.52	-18.28	Upgrade
Depreciation & Amortization	1.19	1.09	1.12	1.3	1.62	Upgrade
Share-Based Compensation	3.45	2.09	2.38	3.13	0.84	Upgrade
Other Operating Activities	-14.27	-13.24	13.8	-24.01	-3.53	Upgrade
Operating Cash Flow	-1.32	-25	-10.29	-26.11	-19.36	Upgrade
Capital Expenditures	-1.15	-0.63	-1.41	-0.66	-0.63	Upgrade
Change in Investments	-15.42	-5	20.44	-19.62	0	Upgrade
Other Investing Activities	-0.14	0.59	-0.11	0.32	-0.26	Upgrade
Investing Cash Flow	-16.71	-5.04	18.92	-19.95	-0.88	Upgrade
Share Issuance / Repurchase	23.95	8.24	46.2	46.21	0	Upgrade
Debt Issued / Paid	0	0	-34.12	-0.22	0	Upgrade
Other Financing Activities	0.71	0	-	0.47	-	Upgrade
Financing Cash Flow	24.67	8.24	12.08	46.47	0	Upgrade
Exchange Rate Effect	-0.11	-0.08	0.01	0.06	0.23	Upgrade
Net Cash Flow	6.52	-21.87	20.72	0.47	-20.02	Upgrade
Free Cash Flow	-2.47	-25.63	-11.69	-26.76	-19.99	Upgrade
Free Cash Flow Margin	-3.77%	-53.80%	-30.49%	-42.55%	-36.54%	Upgrade
Free Cash Flow Per Share	-0.04	-0.53	-0.27	-0.92	-1.35	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).